Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices 31537 

that such articles should not be excluded 

from entry. 

19 U.S.C. 1337(d)(1). A similar 

provision applies to cease and desist 

orders. 19 U.S.C. 1337(f)(1). 

The Commission is soliciting 

submissions on public interest issues 

raised by the recommended relief 

should the Commission find a violation, 

specifically: A limited exclusion order 

directed to certain laparoscopic surgical 

staplers, reload cartridges, and 

components thereof imported, sold for 

importation, and/or sold after 

importation by respondents Intuitive 

Surgical Inc.; Intuitive Surgical 

Operations, Inc.; Intuitive Surgical 

Holdings, LLC; and Intuitive Surgical S. 

De R.L. De C.V.; and cease and desist 

orders directed to the same. Parties are 

to file public interest submissions 

pursuant to 19 CFR 210.50(a)(4). 

The Commission is interested in 

further development of the record on 

the public interest in this investigation. 

Accordingly, members of the public are 

invited to file submissions of no more 

than five (5) pages, inclusive of 

attachments, concerning the public 

interest in light of the ALJ’s 

Recommended Determination on 

Remedy and Bonding issued in this 

investigation on June 8, 2021. 

Comments should address whether 

issuance of the recommended remedial 

orders in this investigation, should the 

Commission find a violation, would 

affect the public health and welfare in 

the United States, competitive 

conditions in the United States 

economy, the production of like or 

directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) Explain how the articles 

potentially subject to the recommended 

remedial orders are used in the United 

States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the recommended orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or thirdparty suppliers have the capacity to 

replace the volume of articles 

potentially subject to the recommended 

orders within a commercially 

reasonable time; and 

(v) explain how the recommended 

orders would impact consumers in the 

United States. 

Written submissions must be filed no 

later than by close of business on July 

8, 2021. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. The Commission’s paper 

filing requirements in 19 CFR 210.4(f) 

are currently waived. 85 FR 15798 

(March 19, 2020). Submissions should 

refer to the investigation number (‘‘Inv. 

No. 337–TA–1167’’) in a prominent 

place on the cover page and/or the first 

page. See Handbook for Electronic 

Filing Procedures, https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf.) Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel, solely for cybersecurity 

purposes. All contract personnel will 

sign appropriate nondisclosure 

agreements. All nonconfidential written 

submissions will be available for public 

inspection on EDIS. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and in Part 210 of the Commission’s 

Rules of Practice and Procedure (19 CFR 

part 210). 

By order of the Commission. 

Issued: June 9, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–12409 Filed 6–11–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–850] 

Importer of Controlled Substances 

Application: Usona Institute 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Usona Institute has applied to 

be registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplemental Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 14, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 14, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on May 10, 2021, Usona 

Institute, 2780 Woods Hollow Road, 

Room 2412, Fitchburg, Wisconsin 

53711–5370, applied to be registered as 

an importer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

5-Methoxy-N-Ndimethyltryptamine.7431 I 

Dimethyltryptamine ... 7435 I 

Psilocybin ................. 7437 I 

Psilocyn .................... 7438 I 

The institute plans to import the 

listed controlled substances to be used 

for research and analytical purposes. 

The materials will not be used for 

clinical trials or bulk manufacture. No 


lotter on DSK11XQN23PROD with NOTICES1
31538 Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices 

other activity for these drug codes is 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–12353 Filed 6–11–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–849] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Fisher Clinical Services, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 14, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 14, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for a hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on May 17, 2021, Fisher 

Clinical Services, Inc., 700A–C Nestle 

Way, Breinigsville, Pennsylvania 

18031–1522, applied to be registered as 

an importer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Marihuana Extract .... 7350 I 

The company plans to import the 

above controlled substance as finished 

dosage forms for clinical trials. No other 

activity for this drug code is authorized 

for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–12350 Filed 6–11–21; 8:45 am] 

BILLING CODE P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (21–037)] 

NASA Astrophysics Advisory 

Committee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

(NASA) announces a meeting of the 

Astrophysics Advisory Committee. This 

Committee reports to the Director, 

Astrophysics Division, Science Mission 

Directorate, NASA Headquarters. The 

meeting will be held for the purpose of 

soliciting, from the scientific 

community and other persons, scientific 

and technical information relevant to 

program planning. 

DATES: Tuesday, June 29, 2021, 11:00 

a.m.–5:00 p.m., Eastern Time; and 

Wednesday, June 30, 2021, 11:00 a.m.– 

5:00 p.m., Eastern Time. 

FOR FURTHER INFORMATION CONTACT: Ms. 

KarShelia Henderson, Science Mission 

Directorate, NASA Headquarters, 

Washington, DC 20546, (202) 358–2355, 

or khenderson@nasa.gov. 

SUPPLEMENTARY INFORMATION: The 

meeting will be virtual and available to 

the public by WebEx and dial-in 

teleconference. On Tuesday, June 29, 

the event address for attendees is: 

https://nasaenterprise.webex.com/

nasaenterprise/j.php?MTID=

m19281c9d7b875a40a767c1af1f5fd5d4, 

the meeting number is 199 024 6323, 

and meeting password is 2bkHspPS@65. 

On Wednesday, June 30, the event 

address for attendees is: https://

nasaenterprise.webex.com/

nasaenterprise/j.php?MTID=

mc4d6d874b2e677b1e6460c8fb1b8df0a, 

the meeting number is 199 642 8616, 

and meeting password is XZgYwCr2@

65. To join by telephone, the numbers 

are: 1–929–251–9612 or 1–415–527– 

5035, for each day. 

The agenda for the meeting includes 

the following topics: 

—Astrophysics Division Update 

—Updates on Specific Astrophysics 

Missions 

—Reports from the Program Analysis 

Groups 

—Report on Science Activation Program 

The agenda will be posted on the 

Astrophysics Advisory Committee web 

page: https://science.nasa.gov/ 

researchers/nac/science-advisorycommittees/apac. 

The public may submit and upvote 

comments/questions ahead of the 

meeting through the website https://

arc.cnf.io/sessions/qgpt/#!/dashboard 

that will be opened for input on June 14, 

2021. 

It is imperative that the meeting be 

held on this date to accommodate the 

scheduling priorities of the key 

participants. 

Patricia Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. 2021–12446 Filed 6–11–21; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL SCIENCE FOUNDATION 

Sunshine Act Meeting 

The National Science Board’s ad hoc 

Committee on Nominating NSB Class of 

2022–2028 (NOMS), hereby gives notice 

of the scheduling of a teleconference for 

the transaction of National Science 

Board business, as follows: 

TIME AND DATE: Thursday, June 17, 2021, 

from 11:30 a.m.–12:00 p.m. EDT. 

PLACE: This meeting will be held by 

teleconference through the National 

Science Foundation, 2415 Eisenhower 

Avenue, Alexandria, VA 22314. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: The agenda 

of the teleconference is: To review the 

master list of NSB Nominees, discuss 

review and rating guidance, and receive 

reviewing assignments. 


lotter on DSK11XQN23PROD with NOTICES1